www.straitstimes.com ·
More Men Getting Hpv Vaccine Amid Growing Awareness of Benefits
Topic context
This topic has been covered 274388 times in the last 7 days across our monitored publishers.
The full article is on the original publisher site.
AI insight
AI-generatedIncreasing male HPV vaccination in Singapore drives demand for the vaccine, benefiting vaccine manufacturers (e.g., Merck, GSK) and healthcare providers offering vaccination services. However, low uptake and cost barriers limit near-term commercial impact. The mechanism is demand_spike for HPV vaccines, but magnitude is small given low baseline penetration.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Males accounted for ~30% of HPV vaccinations at Parkway Shenton clinics in 2025, up from 20% in 2024.
- Hisential clinic reported a rise from about 5 to 30 male patients monthly.
- Overall vaccination rate among eligible males remains below 5%.
- Vaccine cost is approximately $250 per dose.
- HPV vaccine has been available for men in Singapore since 2020.
Mid-term, low baseline uptake and cost barriers limit sustained revenue growth for healthcare providers.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- HEALTHCARE_SERVICESmid
- PHARMA_BIOTECHmid
Related stories
sundaytimes.lk
Economic Woes Stemming From Rupee Slide Stir Spectre of 2022 Crisis
mirror.co.uk
Yann Jennings Allergies Deadly Treatment
adgully.com
Ht Labs Eyes Cyprus as Europes AI Innovation Gateway in Presence of Nikos Christodoulides
yahoo.com
Doj Treasury Investigate Nonprofits Leaders
aninews.in